About this episode
In The Tox Talks we feature expert injectors with significant experience using botulinum toxins. We explore their experience with particular brands, how their techniques have evolved and the subtle nuances of getting the best out of toxins.
In Chapter 7, California plastic surgeon Dr John Joseph shares his experience as a lead clinical study investigator and explains why he believes we have been doing toxins wrong for the past 35 years.
We cover early Botox adoption, why 2.5 mL became the standard dilution, inside clinical trials, on- versus off-label use, the relationship between dose and duration, Galderma and Allergan study findings, why duration plateaus, safety and field of effect, concentrating to extend duration, running multiple dilutions, pricing and practice economics, which toxin to stock, resistance and the future of toxins.
What you'll learn
- Why 2.5 mL became the standard dilution
- How dose relates to duration
- Why toxin duration plateaus
- Safety and field of effect at higher doses
- Running multiple dilutions in practice
- Pricing for longer-lasting results
Topics
- The Tox Talks
- Botulinum toxin
- Dosing
- Dilution
- Clinical trials
- USA
Full transcript
The full transcript for this episode is coming soon.